Literature DB >> 27249077

Open-Label trial on the effects of memantine in adults with obsessive-compulsive disorder after a single ketamine infusion.

Carolyn I Rodriguez1, Amanda Levinson, Jordana Zwerling, Donna Vermes, Helen Blair Simpson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27249077      PMCID： PMC5544938          DOI： 10.4088/JCP.15l10318

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN： 0160-6689            Impact factor:   4.384


× No keyword cloud information.
  13 in total

1.  Memantine for treatment-resistant OCD.

Authors:  Michael Poyurovsky; Ronit Weizman; Abraham Weizman; Lorrin Koran
Journal:  Am J Psychiatry       Date:  2005-11       Impact factor: 18.112

Review 2.  Practice guideline for the treatment of patients with obsessive-compulsive disorder.

Authors:  Lorrin M Koran; Gregory L Hanna; Eric Hollander; Gerald Nestadt; Helen Blair Simpson
Journal:  Am J Psychiatry       Date:  2007-07       Impact factor: 18.112

3.  Defining response in clinical trials for obsessive-compulsive disorder: a signal detection analysis of the Yale-Brown obsessive compulsive scale.

Authors:  David F Tolin; Jonathan S Abramowitz; Gretchen J Diefenbach
Journal:  J Clin Psychiatry       Date:  2005-12       Impact factor: 4.384

4.  Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial.

Authors:  Elias Aboujaoude; John J Barry; Nona Gamel
Journal:  J Clin Psychopharmacol       Date:  2009-02       Impact factor: 3.153

5.  Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study.

Authors:  Ali Ghaleiha; Neda Entezari; Amirhossein Modabbernia; Babak Najand; Neda Askari; Mina Tabrizi; Mandana Ashrafi; Reza Hajiaghaee; Shahin Akhondzadeh
Journal:  J Psychiatr Res       Date:  2012-10-09       Impact factor: 4.791

6.  In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD).

Authors:  Mohammad Haghighi; Leila Jahangard; Hamid Mohammad-Beigi; Hafez Bajoghli; Hassan Hafezian; Alireza Rahimi; Hamid Afshar; Edith Holsboer-Trachsler; Serge Brand
Journal:  Psychopharmacology (Berl)       Date:  2013-03-23       Impact factor: 4.530

7.  Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial.

Authors:  Jamie D Feusner; Lauren Kerwin; Sanjaya Saxena; Alexander Bystritsky
Journal:  Psychopharmacol Bull       Date:  2009

8.  A single-blinded case-control study of memantine in severe obsessive-compulsive disorder.

Authors:  S Evelyn Stewart; Eric A Jenike; Dianne M Hezel; Denise Egan Stack; Nicholas H Dodman; Louis Shuster; Michael A Jenike
Journal:  J Clin Psychopharmacol       Date:  2010-02       Impact factor: 3.153

9.  The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability.

Authors:  W K Goodman; L H Price; S A Rasmussen; C Mazure; R L Fleischmann; C L Hill; G R Heninger; D S Charney
Journal:  Arch Gen Psychiatry       Date:  1989-11

10.  Randomized controlled crossover trial of ketamine in obsessive-compulsive disorder: proof-of-concept.

Authors:  Carolyn I Rodriguez; Lawrence S Kegeles; Amanda Levinson; Tianshu Feng; Sue M Marcus; Donna Vermes; Pamela Flood; Helen B Simpson
Journal:  Neuropsychopharmacology       Date:  2013-06-19       Impact factor: 7.853
View more
  4 in total

Review 1.  Obsessive-compulsive disorder.

Authors:  Dan J Stein; Daniel L C Costa; Christine Lochner; Euripedes C Miguel; Y C Janardhan Reddy; Roseli G Shavitt; Odile A van den Heuvel; H Blair Simpson
Journal:  Nat Rev Dis Primers       Date:  2019-08-01       Impact factor: 52.329

Review 2.  Pharmacotherapeutic Strategies and New Targets in OCD.

Authors:  Christopher Pittenger
Journal:  Curr Top Behav Neurosci       Date:  2021

Review 3.  Glutamate-Modulating Drugs as a Potential Therapeutic Strategy in Obsessive-Compulsive Disorder.

Authors:  Zoya Marinova; De-Maw Chuang; Naomi Fineberg
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

4.  Therapeutic Potentials of Ketamine and Esketamine in Obsessive-Compulsive Disorder (OCD), Substance Use Disorders (SUD) and Eating Disorders (ED): A Review of the Current Literature.

Authors:  Giovanni Martinotti; Stefania Chiappini; Mauro Pettorruso; Alessio Mosca; Andrea Miuli; Francesco Di Carlo; Giacomo D'Andrea; Roberta Collevecchio; Ilenia Di Muzio; Stefano L Sensi; Massimo Di Giannantonio
Journal:  Brain Sci       Date:  2021-06-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.